Download MendeleyDiscovery of a Novel Pyrazole Series of Group X Secreted Phospholipase A2 Inhibitor (Spla2X) Via Fragment Based Virtual Screening
Chen, H., Knerr, L., Akerud, T., Hallberg, K., Bodin, C., Oster, L., Rohman, M., Osterlund, K., Beisel, H.G., Olsson, T., Brengdhal, J., Sandmark, J.(2014) Bioorg Med Chem Lett 24: 5251
- PubMed: 25316315
- DOI: https://doi.org/10.1016/j.bmcl.2014.09.058
- Primary Citation of Related Structures:
4UY1 - PubMed Abstract:
The discovery of potent novel pyrazole containing group X secreted phospholipase A2 inhibitors via structure based virtual screening is reported. Docking was applied on a large set of in-house fragment collection and pharmacophore feature matching was used to filter docking poses. The selected virtual screening hits was run in NMR screening, a potent pyrazole containing fragment hit was identified and confirmed by its complex X-ray structure and the following biochemical assay result. Expansion on the fragment hit has led to further improvement of potency while maintaining high ligand efficiency, thus supporting the further development of this chemical series.
Organizational Affiliation:
Chemistry Innovation Center, Discovery Sciences, AstraZeneca R&D Mölndal, SE-43183 Mölndal, Sweden. Electronic address: Hongming.chen@astrazeneca.com.
